Sinovac Biotech Ltd. (SVA), a Chinese global biopharmaceutical company, announced that it has received a notification letter dated January 2, 2026, from Nasdaq stating that the Company was not in compliance with Nasdaq's Listing Rule 5250(c)(2). This is because Sinovac did not timely file a Form 6-K containing an interim balance sheet and income statement as of the end of its second quarter of 2025.
The company was previously issued a delisting determination letter by the Nasdaq last November 2025, for failing to timely file its annual report on Form 20-F for the year ended December 31, 2024, even after the November 11, 2025, extension deadline.
On November 19, 2025, Sinovac requested a hearing before the Nasdaq Hearings Panel to appeal the Staff Determination.
In response to the request, Nasdaq stated that the Nasdaq Hearings Panel will also consider the matter addressed in the notification letter at a hearing scheduled for January 8, 2026, at which the Company has been invited to present its case.
Sinovac is evaluating the notification Letter and aims to present its plan to the Nasdaq Hearings Panel at the scheduled hearing on January 8.
Trading of the company's common shares on NASDAQ has been halted since February 22, 2019. The stock closed at $6.47 that day.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.